Literature DB >> 8028012

Prevention of age-related V1 myosin isozyme decrement in the adult rat heart.

V Raizada1, D Pathak, A Nakouzi, A Malhotra.   

Abstract

The present investigation was undertaken to determine whether nifedipine could modulate the age-related relative decline in V1 myosin isozyme. Adult rats at age 24 weeks were treated with nifedipine. Myosin isozyme levels (V1, V2, and V3) at age 36 weeks, after 12 weeks of treatment with nifedipine, were compared with age-matched controls without nifedipine. As a natural effect of aging, the V1 percent was reduced from 63 +/- 6 at 16 wks to 29 +/- 3 at 36 wks (P < 0.001). In the 36 week treated Wistar-Kyoto (WKY) rats, the V1 level was 62 +/- 4, which was 47% higher than the age-matched untreated WKY. The V1 content of 36-week treated rats was the same as that of 16-week untreated rats. We conclude that the myosin isozyme changes occurring with aging can be prevented with nifedipine begun in the young adult rat.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8028012     DOI: 10.1006/jmcc.1994.1037

Source DB:  PubMed          Journal:  J Mol Cell Cardiol        ISSN: 0022-2828            Impact factor:   5.000


  3 in total

1.  Age-related difference in cardiac adaptation to chronic hypertension in rats, with and without nifedipine treatment.

Authors:  V Raizada; D Pathak; B Skipper; A Nakouzi; A Malhotra
Journal:  Mol Cell Biochem       Date:  1999-08       Impact factor: 3.396

2.  Age-related left ventricular remodeling and associated risk for cardiovascular outcomes: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Susan Cheng; Verônica R S Fernandes; David A Bluemke; Robyn L McClelland; Richard A Kronmal; João A C Lima
Journal:  Circ Cardiovasc Imaging       Date:  2009-03-26       Impact factor: 7.792

3.  Healthy aging of the left ventricle in relationship to cardiovascular risk factors: The Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Chia-Ying Liu; Shenghan Lai; Nadine Kawel-Boehm; Harjit Chahal; Bharath Ambale-Venkatesh; Joao A C Lima; David A Bluemke
Journal:  PLoS One       Date:  2017-06-22       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.